AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca, in collaboration with Parexel International, is conducting a Phase III clinical study titled ‘Efficacy and Safety of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)’. The study aims to assess the efficacy and safety of Benralizumab, a drug administered subcutaneously, in children aged 6 to under 18 years with severe eosinophilic asthma. This study is significant as it targets a vulnerable population with limited treatment options, potentially improving asthma management in pediatric patients.
The intervention being tested is Benralizumab, an experimental drug administered via subcutaneous injection. It is designed to reduce asthma exacerbations in children with severe eosinophilic asthma by targeting and depleting eosinophils, which are inflammatory cells involved in asthma pathophysiology.
The study follows an interventional, randomized, parallel-group design with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment-focused, comparing Benralizumab against a placebo to evaluate its effectiveness in preventing asthma exacerbations.
The study began on April 5, 2023, with primary completion anticipated in the coming years. The last update was submitted on July 16, 2025, indicating ongoing recruitment and progress. These dates are crucial for tracking the study’s timeline and assessing when results might impact the market.
This study update could positively influence AstraZeneca’s stock performance by strengthening its portfolio in pediatric asthma treatment, a niche yet impactful market. Investors might view this as a strategic move to capture market share in an area with unmet medical needs, potentially enhancing AstraZeneca’s competitive edge over other pharmaceutical companies.
The study is ongoing, with further details available on the ClinicalTrials portal.